Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

BURKINA FASO39Endemicity statusEndemicNon-endemicUncertainAnnual Report on Lymphatic Filariasis 2003LF is a major health problem for Burkina Faso’s populationof approximately 13 million, all of whom are consideredto be at risk. The LF clinical manifestationsevaluated in sentinel sites show hydrocele and lymphoedemaprevalence of 2% and 0.6%, respectively.The health district is designated as the IU. Mapping ofLF completed in 2000 showed that all 53 health districtsare considered LF-endemic. The first round of MDA usingalbendazole and ivermectin began in 2001 in four IUs inthe southern part of the country. In 2002, 14 IUs wereunder the co-administration of the two drugs and an at-riskpopulation of 2.6 million was covered. The third round ofMDA in 2003 covered 31 IUs and 7 074 048 people, with areported coverage of 77.8% (range: 54.9% to 82.6%).Mapping using ICT cards revealed LF prevalence of 5% to57% for new districts that started MDA in 2003, and themf prevalence found in seven new sentinel sites rangedfrom 0.1% to 23.8 %. Between 2001 and 2003, 20 993 drugdistributors were trained, and 2961 people were trainedin disability prevention and control.Chapter 3 Programme implementationTable 3.3 Goal: to eliminate LF from Burkina Faso by 2015Objectives• To interrupt transmission of LF• To prevent LF-associated disabilityStrategies• Social mobilization: to build awareness of the programme is plannedaccording to local characteristics by local experts and backed up, wherepossible, by local political, religious and community leaders• To interrupt transmission using MDA and vector control as a supplementarymeasure, wherever feasible• Disability control, including self-help care involving intensive local hygiene• Building and sustaining partnerships• Programme management by strengthening management and technicalcapacity• Door-to-door drug distribution strategy, with some booths